Please assess the completion status of the following clinical trial:

Trial Title: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented HER2-positive locally advanced or metastatic breast cancer~* Tumor tissue blocks or 15-20 unstained tissue slides for confirmatory central laboratory HER2 status testing and other exploratory assessments~* Prior trastuzumab in any line of therapy (Phase Ib patients only)~* No prior T-DM1 or pertuzumab therapy~* Measurable or evaluable disease~* Cardiac ejection fraction \>=50% by either echocardiogram or multigated acquisition scan~* Life expectancy \>= 90 days as assessed by the investigator~Exclusion Criteria:~* Fewer than 21 days since the last anti-tumor therapy, including chemotherapy, biologic, experimental, immune, hormonal or radiotherapy for the treatment of breast cancer, with the following exceptions: hormone-replacement therapy or oral contraceptives are allowed; palliative radiation therapy involving \<=25% of marrow-bearing bone is allowed if completed within \>= 14 days prior to first study treatment~* History of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins, or any of the excipients that resulted in trastuzumab being permanently discontinued~* Peripheral neuropathy of Grade \>= 2 per NCI CTCAE, Version 3.0, at the time of, or within 3 weeks prior to, the first study therapy (Phase Ib patients)~* Peripheral neuropathy of Grade \>/=1 per NCI CTCAE, Version 3.0, at the time of, or within 3 weeks prior to, the first study therapy (Phase IIa patients)~* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin \> 500 mg/m\^2; Liposomal doxorubicin \> 900 mg/m\^2; Epirubicin \> 720 mg/m\^2~* History of clinically significant cardiac dysfunction~* Brain metastases that are untreated, or progressive, or have required any type of therapy (including radiation, surgery, or steroids) to control symptoms from brain metastases within 60 days prior to the first study treatment.~* History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, basal cell carcinoma, or synchronous or subsequent HER2-positive breast cancer or other malignancy with a similar expected curative outcome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase lb Regimen 1 (Type: EXPERIMENTAL): Participants received trastuzumab emtansine (T-DM1) every three weeks (Q3W) + paclitaxel weekly (QW) intravenously.
- Phase Ib Regimen 2 (Type: EXPERIMENTAL): Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.
- Phase Ib Regimen 3 (Type: EXPERIMENTAL): Participants received T-DM1 QW + paclitaxel QW intravenously.
- Phase Ib Regimen 4 (Type: EXPERIMENTAL): Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously.
- Phase IIa Group A (Type: EXPERIMENTAL): Participants received maximum tolerated dose (MTD) from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m\^2 QW intravenously.
- Phase IIa Group B (Type: EXPERIMENTAL): Participants received MTD from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m\^2 QW + pertuzumab Q3W intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).